FABIO FERNANDES MORATO CASTRO
Projetos de Pesquisa
Unidades Organizacionais
FM, Faculdade de Medicina
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina - Líder
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina - Líder
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
bookPart Anafilaxia(2016) LIMA, Cynthia Mafra Fonseca de; YANG, Ariana Campos; GALVãO, Clóvis Eduardo Santos; CASTRO, Fábio Fernandes MoratobookPart Dermatite Atópica(2016) YANG, Ariana Campos; CASTRO, Fábio Fernandes MoratobookPart Alergia Alimentar(2016) YANG, Ariana Campos; POMIECISNKI, Fabiane; CASTRO, Fábio Fernandes MoratobookPart Rinossinusite Alérgica(2016) GALVãO, Clóvis Eduardo Santos; CASTRO, Fábio Fernandes Morato- Mometasone furoate in the treatment of mild, moderate, or severe persistent allergic rhinitis: a non-inferiority study (PUMA)(2016) ANTILA, Martti Anton; CASTRO, Fabio Morato; SANO, Flavio; MACHADO, Adelmir; FERNANDES, Fatima; ROSARIO FILHO, Nelson Augusto; STELMACH, RafaelIntroduction: Allergic rhinitis is considered the most prevalent respiratory disease in Brazil and worldwide, with great impact on quality of life, affecting social life, sleep, and also performance at school and at work. Objective: To compare the efficacy and safety of two formulations containing mometasone furoate in the treatment of mild, moderate, or severe persistent allergic rhinitis after four weeks of treatment. Methods: Phase III, randomized, non-inferiority, national, open study comparing mometasone furoate in two presentations (control drug and investigational drug). The primary endpoint was the percentage of patients with reduction of at least 0.55 in nasal index score (NIS) after four weeks of treatment. Secondary outcomes included total nasal index score score after four and 12 weeks of treatment; individual scores for symptoms of nasal obstruction, rhinorrhea, sneezing, and nasal pruritus; as well as score for pruritus, lacrimation, and ocular redness after four and 12 weeks of treatment. The study was registered at clinicaltrials.gov with the reference number NCT01372865. Results: The efficacy primary analysis demonstrated non-inferiority of the investigational drug in relation to the control drug, since the upper limit of the confidence interval (CI) of 95% for the difference between the success rates after four weeks of treatment (12.6%) was below the non-inferiority margin provided during the determination of the sample size (13.7%). Adverse events were infrequent and with mild intensity in most cases. Conclusion: The efficacy and safety of investigational drug in the treatment of persistent allergic rhinitis were similar to the reference product, demonstrating its non-inferiority. (C) 2016 Associacao Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial.
conferenceObject Cross-Reactivity Among Cereal Grains(2016) MENDONCA, Juliana Guimaraes; CASTRO, Roberta Almeida; CORDOVA, Pablo Torres; MEIRELES, Paula Rezende; FIGO, Daniele Danella; SANTOS, Keity Souza; KALIL, Jorge; CASTRO, Fabio Fernandes Morato; YANG, Ariana C.bookPart Alergia a Venenos de Insetos(2016) WATANABE, Alexandra Sayuri; CASTRO, Fábio Fernandes Morato